Ficlatuzumab - AVEO Oncology

Drug Profile

Ficlatuzumab - AVEO Oncology

Alternative Names: AV-299; Ficla; SCH-900105

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AVEO Pharmaceuticals
  • Developer AVEO Oncology; AVEO Pharmaceuticals; Dana-Farber Cancer Institute; University of Arizona Cancer Center; University of California at San Francisco; University of Pittsburgh
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Hepatocyte growth factor inhibitors; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Head and neck cancer; Non-small cell lung cancer
  • Phase I Acute myeloid leukaemia; Pancreatic cancer
  • No development reported Lymphoma; Multiple myeloma; Solid tumours
  • Discontinued Glioblastoma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 12 Dec 2017 Ficlatuzumab- AVEO Oncology is available for licensing as of 07 Dec 2017. www.aveooncology.com
  • 07 Dec 2017 Phase-I clinical trials in Pancreatic cancer (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT03316599)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top